LDX is following a growth pattern, it rose from death bed to current level and settled around $0.10. Moving up from $0.10 in increment to $0.005 to $0.30 is most difficult task for every shares and it needs both fundamentals, momentum and few credible announcement. It may not reach anytime soon to $0.30 anytime soon (may be this time of next year), however if Lumox can pull feasibility project for BDI, by next year it can generate 200M revenue which is 4000% of current revenue. This outcome is not far, probably end of November.
Lumos will put everything in its capacity, if this becomes successful, it is just matter of time if it attains its IPO
"The project will build upon preliminary proof-of-concept work conducted by BDI on a novel companion diagnostic biomarker with utility across a range of human health applications. Lumos will conduct feasibility level development studies to generate a prototype test for evaluation with clinical specimens. This initial feasibility stage of the project is worth up to US$200,000 in revenue for Lumosand is expected to complete within approximately four months. If successful, Lumos may be engaged to assist with subsequent stages of the project including product design, development and manufacturing"
